Blood tumor mutational burden and dynamic changes in circulating tumor DNA predict response to pembrolizumab treatment in advanced non-small cell lung cancer

BACKGROUND: The use of immunotherapy targeting the programmed cell death protein-1 (PD-1) and its ligand (PD-L1) has provided new hope for patients with non-small cell lung cancer (NSCLC). However, good biomarkers are needed to identify which patients will benefit from the treatment. In this study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Stensgaard, Simone, Thomsen, Astrid, Helstrup, Sofie, Meldgaard, Peter, Sorensen, Boe S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261859/
https://www.ncbi.nlm.nih.gov/pubmed/37323168
http://dx.doi.org/10.21037/tlcr-22-818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261859/
https://www.ncbi.nlm.nih.gov/pubmed/37323168
http://dx.doi.org/10.21037/tlcr-22-818

Ejemplares similares